Plain-English translation of NCT03443999 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →This trial is evaluating a newer type of heart stent called the Supraflex Family sirolimus-eluting stent. This medication is coated with a special drug that prevents the stent from becoming blocked over time, and the stent itself is made from a stronger, more flexible material that makes it easier for doctors to place. The study is following thousands of real patients who receive this stent to make sure it is both safe and effective.
Older heart stents sometimes caused long-term problems because their coating didn't fully break down in the body. This newer stent was designed to address that issue by using a coating that safely dissolves over time, combined with a stronger, more flexible material that may work better for more patients.
You likely qualify if…
You likely don't qualify if…
Once your doctor places the stent in your heart arteries, you will be asked to attend follow-up visits so the research team can monitor how well the stent is working and check for any side effects. You will likely have imaging tests and office visits at scheduled intervals. The study is enrolling up to 10,000 patients in the Netherlands and will track your health outcomes over time to help doctors understand how safe and effective this treatment is for a wide range of patients.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Netherlands